Dipharma completes R&D expansion
Italian CDMO Dipharma Francis has completed of the expansion of its R&D centre for small molecules at its headquarters site in Baranzate, near Milan. This boosts lab space for analytical R&D activities by over 130%. The equipment includes a new 500 MHz NMR and the centre is managed via cloud-based integrated data systems.
Dipharma added that the expansion will both strengthen its analytical capabilities and “broaden expertise for the development of new organic synthesis methods and technology to target and offer a wider range of new APIs and advanced intermediates”. Its R&D team in Italy has grown by over 40% in Italy since 2020, with further expansion in the US.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
